particle-characterization-services-biologics
Biologic drug development is complex, with particle formation and regulatory hurdles posing significant challenges. Discover how expert particle characterization services can help you master formulation, ensure product stability, and meet strict compliance standards. Read on to navigate these complexities.
Menu
Mastering Biologic Formulation: A Guide to Particle Characterization Services
Current Situation
Typical Market Trends
Current Challenges and How They Are Solved
How Leukocare Can Support These Challenges
Value Provided to Customers
FAQ
Mastering Biologic Formulation: A Guide to Particle Characterization Services
The path of a biologic drug from an idea to a commercial product is filled with complexities. As leaders in CMC and Drug Product Development, you are at the forefront, guiding products through a maze of scientific, regulatory, and market pressures. The choices made early in development cast a long shadow, influencing a product's eventual success. This article examines the current state of biologic drug development, identifies important market trends, and discusses how strategic partnerships can help manage the hurdles of particle characterization.
Current Situation
Developing biologics takes a lot of effort. The molecules are large and inherently unstable, making formulation a delicate balancing act. [1] The main goal is to create a stable, effective product that meets strict regulatory standards. Particle formation, a common result of protein aggregation, is a major concern. These particles can range from sub-visible to visible and can affect the product's safety and effectiveness.
Regulatory bodies like the FDA and EMA have strict guidelines on particulate matter. [31, 5] For parenteral drugs, USP <788> sets specific limits for subvisible particles, requiring that products for injection have no more than 6000 particles per container that are 10 μm or larger and no more than 600 particles per container that are 25 μm or larger. Meeting these standards is not just about compliance; it's vital for patient safety, as particles can trigger immune responses. [7, 8, 27]
The physical and chemical stresses of manufacturing, such as agitation, freezing, and thawing, can all contribute to particle formation. Even the container closure system can be a source of particles, through interactions with silicone oil lubricants or from the glass itself. [9, 10]
Typical Market Trends
The biologics market is growing, with more and more complex molecules like monoclonal antibodies and new types of treatments, such as viral vectors and RNA-based therapies, being developed. [11, 12, 13] This growth means more attention is paid to the details of how formulations are made and how drugs are delivered. [1, 14, 15] Also, we're seeing a shift towards higher concentration formulations. This brings challenges like a greater chance of protein clumping and thicker solutions.
Self-administration and home-use drug delivery devices are getting more common, so we need strong formulations that can handle different storage and handling conditions. This also means we need to pay more attention to how the drug product interacts with its container and the delivery device. [12]
People are also realizing more and more how important it is to characterize products early on. [17] Spotting potential problems with clumping and particle formation early in development can stop expensive delays later. This has led to the adoption of a wider range of analytical techniques to get a more complete picture of a product's stability.
Current Challenges and How They Are Solved
A main challenge in biologics development is handling protein clumping and the particles that form from it. [18, 19] Proteins are sensitive molecules, and various stresses during manufacturing and storage can cause them to clump together. [20, 24] These aggregates can reduce the product's effectiveness and, more seriously, cause an unwanted immune response in patients. [27, 8]
To address this, companies use many different analytical tools to monitor particles. [23] Techniques like size-exclusion chromatography (SEC), dynamic light scattering (DLS), and flow imaging microscopy help to detect and characterize particles of different sizes. SEC is often used for detecting and quantifying smaller, soluble aggregates, while flow imaging can provide information on the size and shape of larger, subvisible particles. [20, 24] Using a combination of these orthogonal methods gives a more complete picture of the particle population.
Another challenge is the limited amount of material available for testing, especially in early development. This means we need to use analytical methods that only need tiny samples. High-concentration formulations also make some analytical methods harder to use due to their viscosity and optical properties. [9]
Finally, figuring out why particles form is crucial to stopping it. [31, 5] Particles can come from the protein itself, from excipients, or from contact with various surfaces during manufacturing and storage. Careful process design and selection of appropriate container materials can help keep these risks low. [27, 8] The use of surfactants like polysorbate 80 can also help prevent particle formation caused by interfacial stress. [13]
How Leukocare Can Support These Challenges
Tackling the challenges of particle characterization means you need a partner who gets the science and the bigger picture. [10] At Leukocare, we work as an extension of your team, providing not just data, but actionable insights to guide your development program.
Our approach is built on a deep understanding of formulation science and protein stability. [28] We use a suite of advanced analytical methods, including AI-based stability prediction, to characterize your molecule and identify potential risks early. This allows us to design tailored formulation strategies that address your specific challenges, whether you are working with a standard monoclonal antibody or a novel modality like a viral vector or RNA therapeutic.
If you're a fast-track biotech, the pressure to move quickly is huge. Our data-driven formulation development can help you reach your milestones faster, with a robust formulation designed for regulatory success. We provide the strategic guidance needed to make confident decisions under pressure.
For a small biotech without many internal resources, we can be your dedicated formulation team. We provide clear communication and proactive solutions, taking the burden of formulation development off your shoulders so you can focus on other critical path activities.
Even for larger pharma companies with established teams, we can provide specialized support for challenging projects. Whether it's tackling a new modality or providing overflow capacity, we integrate seamlessly with your existing workflows to deliver reliable, data-driven results.
Value Provided to Customers
Speed and Efficiency A data-driven approach accelerates formulation development, helping you reach your milestones faster.
De-risked Development By identifying and addressing potential formulation issues early, you can reduce the risk of costly setbacks later in development. [28]
A Strategic Partner We offer more than just data; we provide the insights and guidance to support your decision-making throughout the development process. [28]
Confidence in Your Formulation A well-characterized formulation provides a solid foundation for a successful BLA submission and a commercially viable product. [28]
FAQ
What is particle characterization in biopharmaceutical development?
Particle characterization involves detecting, sizing, counting, and identifying visible and subvisible particles in drug products. [28] This is vital for making sure the product is safe and effective and meets regulations, because particles can come from the main drug ingredient, other ingredients, or the manufacturing process. [29, 3]
Why is particle analysis so important for biologics?
The size and number of particles in a biologic can directly impact its safety and effectiveness. Aggregated proteins can lead to a loss of efficacy and may cause an immunogenic response in patients. [3, 30] Regulatory agencies have strict limits on the number of particles allowed in injectable drugs. [23]
What are the main analytical techniques used for particle characterization?
Many techniques are used to cover different particle sizes. Size-exclusion chromatography (SEC) is a standard method for quantifying soluble aggregates. Dynamic light scattering (DLS) is used to measure the size distribution of particles in a solution. [20, 24] For subvisible particles, light obscuration and flow imaging microscopy are commonly used to count and characterize particles. [20, 24]
How does formulation impact particle formation?
The formulation plays a central role in keeping proteins stable and preventing clumping. Excipients such as surfactants can reduce the formation of particles caused by stress at interfaces. [1] The pH and ionic strength of the formulation are also critical factors that can influence protein stability. [10]
What are the regulatory expectations for particles in biologics?
Regulatory bodies like the FDA and EMA have clear rules for particle control in parenteral products. For example, USP chapter <788> sets specific limits for subvisible particles at ≥10 µm and ≥25 µm. [32, 6] Manufacturers are expected to have a complete plan to keep particles low throughout the product's life. [7, 33, 34]
